ReviewAntibiotics (Basel, Switzerland)2020
Plant Secondary Metabolites in the Battle of Drugs and Drug-Resistant Bacteria: New Heroes or Worse Clones of Antibiotics?
Review in Antibiotics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 254 citations in OpenAlex.
- Plant-Mediated Production of Antibacterial Nanomaterials Fulfilling a Reactive Oxygen Species Strategy.International journal of molecular sciences · 2026Review
- Chemical profile and bacterial potential of Psidium cattleyanum leaf extract against multidrug-resistant Staphylococcus aureus.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- Antifungal and Profungal Potentials of Acetone-Extracted Complexes of Lichen Substances on MacromyceteMolecules (Basel, Switzerland) · 2026Article
- Plant-Derived Compounds as Antibiotic Adjuvants Against Drug-Resistant ESKAPE Pathogens: Mechanisms of Action, Synergistic Strategies, and Translational Challenges.Antibiotics (Basel, Switzerland) · 2026Review
- Co-development of efflux pump inhibitors with antibiotics on targeting structural and mutational aspects of AcrB subunit.Molecular diversity · 2026Article
- Bacterial secondary metabolites as resistance-modifying adjuvants: microbial origins, molecular mechanisms, and translational relevance.Frontiers in microbiology · 2026Review
- Medicinal plants as biological and socio-ecological components of One Health.Frontiers in pharmacology · 2026Review
- Article
- A Critical Review of Quorum-Sensing Inhibition Strategies in Klebsiella Pneumoniae.Current microbiology · 2025Review
- Menthol's disruptive effects on kanamycin-resistant Escherichia coli energy metabolism and ion fluxes.Biophysical reports · 2025Article
- Screening of Secondary Metabolites with Synergistic Potential Associated with Amoxicillin: An In Vitro and In Silico Approach.Current microbiology · 2025Article
- Review
- From Hue to Health: Exploring the Therapeutic Potential of Plant-Pigment-Enriched Extracts.Microorganisms · 2025Article
- Unlocking potent anti-tuberculosis natural products through structure-activity relationship analysis.Natural products and bioprospecting · 2025Review
- Nutraceutical Potential ofMetabolites · 2025Article
- Chromatographic fingerprinting and antibiofilm effect of Ziziphus jujuba fraction on Pseudomonas aeruginosa.AMB Express · 2025Article
- Advancements in Cyclodextrin Complexes with Bioactive Secondary Metabolites and Their Pharmaceutical Applications.Pharmaceutics · 2025Review
- Comprehensive metabolite profiling and evaluation of anti-nociceptive and anti-inflammatory potencies ofHeliyon · 2025Article
- Quorum Quenching ofPathogens (Basel, Switzerland) · 2025Article
- Antibacterial Potential of Crude Extracts fromMicroorganisms · 2025Article
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infectious diseases that are caused by bacteria are an important cause of mortality and morbidity in all regions of the world. Bacterial drug resistance has grown in the last decades, but the rate of discovery of new antibiotics has steadily decreased. Therefore, the search for new effective antibacterial agents has become a top priority. The plant kingdom seems to be a deep well for searching for novel antimicrobial agents. This is due to the many attractive features of plants: they are readily available and cheap, extracts or compounds from plant sources often demonstrate high-level activity against pathogens, and they rarely have severe side effects. The huge variety of plant-derived compounds provides very diverse chemical structures that may supply both the novel mechanisms of antimicrobial action and provide us with new targets within the bacterial cell. In addition, the rapid development of modern biotechnologies opens up the way for obtaining bioactive compounds in environmentally friendly and low-toxic conditions. In this short review, we ask the question: do antibacterial agents derived from plants have a chance to become a panacea against infectious diseases in the "post-antibiotics era".
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.